Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126675701 | 12667570 | 1 | I | 2015 | 20160806 | 20160819 | 20160819 | EXP | CA-HQ SPECIALTY-CA-2016INT000808 | INTERCHEM | 52.00 | YR | F | Y | 0.00000 | 20160819 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126675701 | 12667570 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 1.0714 MG (7.5 MG, 1 IN 1 W) | 201749 | 7.5 | MG | ||||||||
| 126675701 | 12667570 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 2.1429 MG (15 MG, 1 IN 1 W) | 201749 | 15 | MG | ||||||||
| 126675701 | 12667570 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 2.1429 MG (15 MG, 1 IN 1 W) | 201749 | 15 | MG | ||||||||
| 126675701 | 12667570 | 4 | SS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 200 MG, BID | 0 | 200 | MG | ||||||||
| 126675701 | 12667570 | 5 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | UNK | Y | 0 | |||||||||
| 126675701 | 12667570 | 6 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, BID | Y | U | 0 | 5 | MG | ||||||
| 126675701 | 12667570 | 7 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, BID | Y | U | 0 | 5 | MG | ||||||
| 126675701 | 12667570 | 8 | C | TYLENOL WITH CODEINE | ACETAMINOPHENCODEINE PHOSPHATE | 1 | UNK | 0 | |||||||||||
| 126675701 | 12667570 | 9 | C | MORPHINE | MORPHINE | 1 | UNK | 0 | |||||||||||
| 126675701 | 12667570 | 10 | C | APO-WARFARIN | WARFARIN SODIUM | 1 | UNK | 0 | |||||||||||
| 126675701 | 12667570 | 11 | C | PREDNISONE. | PREDNISONE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126675701 | 12667570 | 1 | Rheumatoid arthritis |
| 126675701 | 12667570 | 4 | Rheumatoid arthritis |
| 126675701 | 12667570 | 5 | Rheumatoid arthritis |
| 126675701 | 12667570 | 6 | Rheumatoid arthritis |
| 126675701 | 12667570 | 8 | Pain |
| 126675701 | 12667570 | 9 | Product used for unknown indication |
| 126675701 | 12667570 | 10 | Product used for unknown indication |
| 126675701 | 12667570 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126675701 | 12667570 | OT |
| 126675701 | 12667570 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126675701 | 12667570 | Abdominal pain upper | |
| 126675701 | 12667570 | Activities of daily living impaired | |
| 126675701 | 12667570 | Alopecia | |
| 126675701 | 12667570 | Cough | |
| 126675701 | 12667570 | Diarrhoea | |
| 126675701 | 12667570 | Drug ineffective | |
| 126675701 | 12667570 | Duodenogastric reflux | |
| 126675701 | 12667570 | Fatigue | |
| 126675701 | 12667570 | Feeling abnormal | |
| 126675701 | 12667570 | Laryngeal mass | |
| 126675701 | 12667570 | Oropharyngeal pain | |
| 126675701 | 12667570 | Pneumothorax | |
| 126675701 | 12667570 | Pulmonary embolism | |
| 126675701 | 12667570 | Pulmonary mass | |
| 126675701 | 12667570 | Rheumatoid arthritis | |
| 126675701 | 12667570 | Rosacea | |
| 126675701 | 12667570 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126675701 | 12667570 | 2 | 20160710 | 0 | ||
| 126675701 | 12667570 | 6 | 20160304 | 20160418 | 0 | |
| 126675701 | 12667570 | 7 | 20160518 | 0 |